News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Reports Third Quarter 2017 Financial Results
Management to host conference call today at 4:30 p.m. ET
View HTML
Toggle Summary Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting
STAMFORD, Conn. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017
STAMFORD, Conn. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
Study to inform dose selection and design of Phase 2 trial in non-hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP)
View HTML
Toggle Summary Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
Data from respiratory safety trial of I.V. CR845 to be detailed in oral presentation
View HTML
Toggle Summary Cara Therapeutics to Present Data at Kidney Week 2017
STAMFORD, Conn. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Phase 3 pivotal program in hemodialysis patients expected to commence in Q4 2017
View HTML
Toggle Summary Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
STAMFORD, Conn. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Participate in September Medical Meetings
Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek STAMFORD, Conn. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed
View HTML
Toggle Summary Cara Therapeutics Reports Second Quarter 2017 Financial Results
Conference call today at 4:30 p.m. ET
View HTML